William Kennedy

Dr. Kennedy has more than 15 years of experience in biopharmaceutical clinical research & development across several therapeutic areas including infectious disease, immunology, and vaccine development. Prior to joining Excision, Dr. Kennedy served as Vice President, Development at Calcilytix, which is developing treatments to manage calcium homeostasis. He was Vice President, Clinical Development at Audentes Therapeutics where he was Clinical Leader in the Company’s AAV-directed gene replacement therapy for two clinical programs using AAV vectors for Crigler Najjar Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia.

Prior to that, Dr. Kennedy was Senior Director, Clinical Development at Alios BioPharma/Janssen Pharmaceuticals, where he was responsible for managing early clinical trials in chronic hepatitis B, including small molecules and therapeutic vaccines for functional cure. He was a Medical Director and Senior Medical Director for more than five years at Genentech, where he was responsible for early clinical development of treatments for autoimmune disorders such as rheumatoid arthritis and lupus erythematosus. Prior to that, he served as Associate Medical Director and Medical Director at Merck & Co., where he was responsible for early clinical trials of treatments to treat neurological conditions including the development of the FDA approved sedative, suvorexant.

Dr. Kennedy earned his M.D. at Stanford University School of Medicine and was a fellow and attending physician at Yale University School of Medicine focused on pediatric infectious diseases.